RS54875B1 - Liofilizovane formulacije fgf-18 - Google Patents

Liofilizovane formulacije fgf-18

Info

Publication number
RS54875B1
RS54875B1 RS20160453A RSP20160453A RS54875B1 RS 54875 B1 RS54875 B1 RS 54875B1 RS 20160453 A RS20160453 A RS 20160453A RS P20160453 A RSP20160453 A RS P20160453A RS 54875 B1 RS54875 B1 RS 54875B1
Authority
RS
Serbia
Prior art keywords
fgf
freeze
dried formulations
formulations
dried
Prior art date
Application number
RS20160453A
Other languages
English (en)
Inventor
Alessandra Cerreti
Rio Alessandra Del
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47356563&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS54875(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of RS54875B1 publication Critical patent/RS54875B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Stabilna liofilizovana formulacija koja uključuje FGF-18, fosfatni pufer koji čini da vrednost pH ostane na između 7,0 i 7,5, poloksamer 188 i saharoza.Prijava sadrži još 11 patentnih zahteva.
RS20160453A 2011-06-17 2012-06-15 Liofilizovane formulacije fgf-18 RS54875B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP11170437 2011-06-17
US201161499216P 2011-06-21 2011-06-21
EP12728509.6A EP2720710B1 (en) 2011-06-17 2012-06-15 Freeze-dried formulations of fgf-18
PCT/EP2012/061495 WO2012172072A1 (en) 2011-06-17 2012-06-15 Freeze-dried formulations of fgf-18

Publications (1)

Publication Number Publication Date
RS54875B1 true RS54875B1 (sr) 2016-10-31

Family

ID=47356563

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20160453A RS54875B1 (sr) 2011-06-17 2012-06-15 Liofilizovane formulacije fgf-18

Country Status (31)

Country Link
US (2) US9326944B2 (sr)
EP (2) EP3056211A1 (sr)
JP (1) JP5981538B2 (sr)
KR (1) KR102019520B1 (sr)
CN (2) CN107715104A (sr)
AR (1) AR086956A1 (sr)
AU (1) AU2012268987B2 (sr)
BR (1) BR112013032400B1 (sr)
CA (1) CA2836667C (sr)
CL (1) CL2013003618A1 (sr)
CO (1) CO6940377A2 (sr)
CY (1) CY1117933T1 (sr)
DK (1) DK2720710T3 (sr)
EA (1) EA024937B1 (sr)
EC (1) ECSP14013157A (sr)
ES (1) ES2575732T3 (sr)
HR (1) HRP20160566T1 (sr)
HU (1) HUE028355T2 (sr)
IL (1) IL229977A (sr)
MX (1) MX338017B (sr)
MY (1) MY170630A (sr)
PE (1) PE20141265A1 (sr)
PL (1) PL2720710T3 (sr)
PT (1) PT2720710E (sr)
RS (1) RS54875B1 (sr)
SG (1) SG195021A1 (sr)
SI (1) SI2720710T1 (sr)
TW (1) TWI527590B (sr)
UA (1) UA113174C2 (sr)
WO (1) WO2012172072A1 (sr)
ZA (1) ZA201308698B (sr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI527590B (zh) * 2011-06-17 2016-04-01 艾瑞斯貿易公司 Ｆｇｆ－１８之凍乾調配物
CA2934638C (en) * 2013-12-24 2022-07-12 Ares Trading S.A. Fgf-18 formulation in alginate/collagen hydrogels
KR20180035911A (ko) * 2015-08-13 2018-04-06 메르크 파텐트 게엠베하 Fgf-18 화합물을 포함하는 조합 조성물
DK3706710T3 (da) * 2017-11-10 2024-07-08 Novartis Ag Formuleringer med forlænget frigivelse til intraartikulære anvendelser
CN109836487B (zh) * 2019-03-01 2022-06-17 重庆派金生物科技有限公司 一种人成纤维细胞生长因子18及其可溶性重组表达方法、制备方法、制剂和应用
CN112121150A (zh) * 2019-06-24 2020-12-25 杭州生物医药创新研究中心 一种成纤维细胞生长因子10冻干粉
CN113304063A (zh) * 2021-04-23 2021-08-27 四川省恩乐生物工程有限公司 一种用于肌肤美容抗衰老的组合物及其制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217954A (en) * 1990-04-04 1993-06-08 Scios Nova Inc. Formulations for stabilizing fibroblast growth factor
GB9015824D0 (en) 1990-07-18 1990-09-05 Erba Carlo Spa Stable pharmaceutical compositions containing a fibroblast growth factor
PT2275119E (pt) 1995-07-27 2013-11-21 Genentech Inc Formulação de proteína liofilizada isotónica estável
US20010056066A1 (en) * 1996-07-26 2001-12-27 Smithkline Beecham Corporation Method of treating immune cell mediated systemic diseases
CA2269083C (en) 1996-10-16 2009-06-09 Zymogenetics, Inc. Novel fgf homologs
CN1184673A (zh) * 1996-12-13 1998-06-17 中国医科大学 Fgf粗提多肽生长因子混合物及其提取工艺
JP2002527401A (ja) * 1998-10-13 2002-08-27 カイロン コーポレイション Ｆｇｆの脈管形成的に有効な単位用量および投与方法
WO2001039788A2 (en) 1999-12-02 2001-06-07 Zymogenetics, Inc. Methods for targeting cells that express fibroblast growth receptor-3 or-2
CN1303714A (zh) * 2000-01-13 2001-07-18 重庆多泰制药有限公司 Ii型胶原蛋白口服胃溶制剂
AU2001286996A1 (en) * 2000-08-31 2002-03-13 Chiron Corporation Stabilized fgf formulations containing reducing agents
ES2338218T3 (es) * 2001-07-25 2010-05-05 Facet Biotech Corporation Formulacion farmacologica liofilizada estable de anticuerpos igg daclizumab.
DE10204792A1 (de) * 2002-02-06 2003-08-14 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Immuncytokine
JP4754823B2 (ja) * 2002-10-07 2011-08-24 ザイモジェネティクス， インコーポレイテッド Ｆｇｆ１８の投与方法
EP1598074B1 (en) * 2003-02-28 2019-01-02 Chugai Seiyaku Kabushiki Kaisha Stabilized protein-containing formulations
EA012281B1 (ru) * 2004-06-01 2009-08-28 Арес Трейдинг С.А. Способ стабилизации белков
PL2586456T3 (pl) * 2004-10-29 2016-07-29 Ratiopharm Gmbh Remodeling i glikopegilacja czynnika wzrostu fibroblastów (FGF)
US7858341B2 (en) * 2004-12-10 2010-12-28 Zymogenetics, Inc. FGF18 production in prokaryotic hosts
EP1962886B2 (en) * 2005-12-20 2022-02-23 Bristol-Myers Squibb Company Stable protein formulations
JP4729740B2 (ja) * 2006-01-11 2011-07-20 独立行政法人産業技術総合研究所 受容体特異性を変化させたミュータント増殖因子およびそれを含有する医薬組成物
PT1986612E (pt) 2006-02-07 2012-11-06 Shire Human Genetic Therapies Composição estável de glucocerebrosidase
KR101419961B1 (ko) 2006-08-25 2014-07-30 아레스 트레이딩 에스.에이. Ｆｇｆ-18 로 연골 질환의 치료
CA2682147C (en) * 2007-03-30 2017-08-08 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
SI2068909T1 (sl) * 2007-03-30 2012-09-28 Ambrx Inc Modificirani fgf-21 polipeptidi in njihova uporaba
CN101181280B (zh) * 2007-11-23 2010-07-14 深圳万乐药业有限公司 吡柔比星冻干制剂及其制备方法
MY171841A (en) * 2007-12-21 2019-11-04 Hoffmann La Roche Antibody formulation
TWI527590B (zh) * 2011-06-17 2016-04-01 艾瑞斯貿易公司 Ｆｇｆ－１８之凍乾調配物

Also Published As

Publication number Publication date
AU2012268987B2 (en) 2016-09-08
MX2013014894A (es) 2014-09-01
CA2836667C (en) 2020-01-14
MX338017B (es) 2016-03-29
AR086956A1 (es) 2014-02-05
CY1117933T1 (el) 2017-05-17
US9326944B2 (en) 2016-05-03
WO2012172072A1 (en) 2012-12-20
PT2720710E (pt) 2016-06-17
CO6940377A2 (es) 2014-05-09
ZA201308698B (en) 2016-02-24
EP2720710B1 (en) 2016-03-23
NZ617992A (en) 2015-09-25
JP2014522807A (ja) 2014-09-08
KR102019520B1 (ko) 2019-11-04
KR20140041600A (ko) 2014-04-04
SG195021A1 (en) 2013-12-30
JP5981538B2 (ja) 2016-08-31
IL229977A (en) 2017-01-31
PL2720710T3 (pl) 2016-09-30
EP3056211A1 (en) 2016-08-17
TW201302217A (zh) 2013-01-16
CN107715104A (zh) 2018-02-23
EA024937B1 (ru) 2016-11-30
MY170630A (en) 2019-08-21
CA2836667A1 (en) 2012-12-20
BR112013032400A2 (pt) 2016-11-22
CN103619347A (zh) 2014-03-05
EA201490032A1 (ru) 2014-05-30
UA113174C2 (xx) 2016-12-26
CL2013003618A1 (es) 2014-07-04
DK2720710T3 (en) 2016-06-27
US20160228374A1 (en) 2016-08-11
EP2720710A1 (en) 2014-04-23
HUE028355T2 (en) 2016-12-28
HRP20160566T1 (hr) 2016-06-17
TWI527590B (zh) 2016-04-01
PE20141265A1 (es) 2014-09-29
SI2720710T1 (sl) 2016-07-29
ES2575732T3 (es) 2016-06-30
US20140121162A1 (en) 2014-05-01
BR112013032400B1 (pt) 2021-07-20
ECSP14013157A (es) 2014-02-28

Similar Documents

Publication Publication Date Title
RS54875B1 (sr) Liofilizovane formulacije fgf-18
BR112018077266A2 (pt) composições compreendendo cepas bacterianas
BR112018005316A2 (pt) ?uso de lisina para restabelecer/aumentar a atividade antibacteriana na presença de surfactante pulmonar de antibióticos inibidos desse modo?
BR112015009924A2 (pt) formulações de proteína imunoglobulina de domínio variável duplo estáveis
DOP2016000287A (es) Composiciones y métodos para modular la expresión de ttr y vh
MX2019007187A (es) Composiciones para el cuidado bucal.
BR112015025854A2 (pt) flagelina de roseburia e modulação imunológica
MX2019011219A (es) Administracion rapida y controlada de composiciones con efectos sequito restaurados.
BR112014021325A2 (pt) Formulação farmacêutica líquida e formulação liofilizada
BR112015023391A2 (pt) formulações compreendendo conjugado droga-anticorpo anti-egfr
FR2998570B1 (fr) Peptides, compositions les comprenant et utilisations notamment cosmetiques propigmentantes
EP3725321A4 (en) COMPOSITION WITH A BACTERIUM OF THE GENUS BIFIDOBACTERIUM AS THE ACTIVE SUBSTANCE
CO6280406A2 (es) Polipeptidos anti-microbianos para uso en el tratamiento de transtornos microbianos
BR112012029517A2 (pt) formulações de fragrância, métodos de fabricação e artigos compreendendo as mesmas.
AR087745A1 (es) Composiciones y metodos que comprenden una variante de enzima lipolitica
UY34332A (es) Composiciones y métodos para controlar malezas co mprendiendo un polinucleótido y agente de transfe rencia, y que modulan la fitoeno desaturasa?.
BR112012019190A2 (pt) composições de cuidado oral.
EP2994142A4 (en) Antibiotic and anti-parasitic agents that modulate class ii fructose 1,6-bisphosphate aldolase
BR112012019997A2 (pt) composições de cuidado oral
BR112014014410A2 (pt) composições e métodos que compreendem uma variante de enzima lipolítica
BR112016026811A2 (pt) formulação de anticorpo
BR112012023910A2 (pt) preparações cosméticas ou dermatológicas com um teor de um ou mais derivados de tiazol
MX350170B (es) Composición inmunogénica estable de antígenos de staphylococcus aureus.
EP3878445A3 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
AR092897A1 (es) Composiciones inmunogenicas